Daily skin care habits and the risk of skin eruptions and symptoms in cancer patients

Byun, Hee Jin; Lee, H.J.; Yang, Jong In; Kim, K.H.; Park, K.O.; Park, S.M.; Lee, K.E.; Choi, Ji-Yeob; Noh, D-Y; Cho, Kil Ho

doi:10.1093/annonc/mds141

Cited by 10 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each item is scored from 0 to 3 (total score range: 0-27). According to the total score, the severity of depression symptoms is categorized as one of five levels: minimal (0-4), mild (5-9), moderate (10)(11)(12)(13)(14), moderately severe (15)(16)(17)(18)(19), and severe (20)(21)(22)(23)(24)(25)(26)(27) [20]. According to a meta-analysis that determined the diagnostic accuracy of the PHQ-9 using standardized diagnostic interviews [22], a cut-off score of 10 is the most widely validated for the detection of MDS (16 studies employed this cut-off; sensitivity: 0.85; specificity: 0.89).…”

Section: Methodsmentioning

confidence: 99%

Correlates of oncologist-issued referrals for psycho-oncology services: what we learned from the electronic voluntary screening and referral system for depression (eVSRS-D)

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Correlates of oncologist-issued referrals for psycho-oncology services: what we learned from the electronic voluntary screening and referral system for depression (eVSRS-D)

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Targeted anticancer therapy has paved the way for a new era of anticancer treatment by specifically acting on therapeutic targets or biologi-cal pathways with minimal adverse effects on normal tissues (19). However, cutaneous side effects from the novel treatments are increasing (2,6,9). Among these treatment methods, EGFRIs show various significant cutaneous toxicities as EGFR is highly expressed on the (The bottom and top portion of the boxes represent the first and third quartiles; the band inside the box is the median; the upper and lower whiskers show the highest and lowest results within 1.5 interquartile range of the upper and lower quartile; the square is the mean; the dot is the outlier; the notch means 95% CI of the median).…”

Section: Discussionmentioning

confidence: 99%

“…C ancer patients, who receive anticancer agents, frequently suffer from various systemic toxicities, such as nausea, mucositis, myelosuppression, and many cutaneous manifestations, including pruritus (1,2). Pruritus, an unpleasant sensation provoking the desire to scratch, is one of the most common cutaneous symptoms manifested during the anticancer therapy (3).…”

mentioning

confidence: 99%

“…In contrast to the classic anticancer chemotherapy that non-specifically damages cancer cells, as well as rapidly proliferating normal cells, the new targeted anticancer agents selectively block signal pathways associated with specific cancer growth and progression, thus successfully reducing systemic adverse events (9). However, targeted anticancer agents frequently induce cutaneous side effects, resulting in clinical problems for oncologists and dermatologists (2,9). In particular, drug-induced pruritus has been reported to occur more frequently with targeted anticancer agents than non-targeted agents (4,10,11).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pruritus in Patients Under Targeted Anticancer Therapy: A Multidimensional Analysis Using the 5-D Itch Scale

et al. 2019

View full text Add to dashboard Cite

Pruritus is a common symptom in patients undergoing targeted anticancer therapy. In this study, we aimed to assess the features of pruritus in patients undergoing targeted anticancer. A total of 374 cancer patients completed the survey, of which 108 were treated with targeted therapy. A total of 205 (54.8%) patients had pruritus, of which 66 were under targeted therapy. Epidermal growth factor receptor inhibitor users showed the highest prevalence rate of itching, NRS score for itching and 5-D itch score. This study showed that patients receiving epidermal growth factor inhibitors suffer from pruritus frequently and severely. Pruritus is a very common symptom in patients, undergoing targeted anticancer therapy. However, the characteristics of pruritus, according to the targeted anticancer agents, are still unclear. The objective of this study was to determine the characteristics of pruritus, induced by targeted anticancer agents, using a questionnaire-based survey. The survey was administered to cancer patients currently receiving anticancer agents. Medical records were also reviewed. A total of 374 cancer patients completed the survey, of which 108 were treated with the targeted therapy. A total of 205 patients had pruritus, of which 66 were under the targeted therapy. Epidermal growth factor receptor inhibitor (EGFRI) users showed the highest prevalence rate of itching and numeric rating scale score for itching. The 5-D itch score was also highest among users of EGFRIs. In conclusion, patients receiving EG-FRIs suffer from severe pruritus frequently. They not only experienced long lasting and intense itching, causing sleep discomfort, but also developed itching at specific body sites.

show abstract

“…Patients with cancer undergoing treatment with anticancer agents often experience various skin problems, such as pruritus, dry skin, facial papulopustules, paronychia, etc. They are at high risk of skin problems, because anticancer agents affect not only cancer cells, but also rapidly proliferating skin cells [ 1 - 4 ]. To date, significant progress has been made in the development of anticancer agents.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study

et al. 2018

View full text Add to dashboard Cite

PurposePatients treated with anticancer agents often experience a variety of treatment-related skin problems, which can impair their quality of life.Materials and MethodsIn this cross-sectional study, Dermatology Life Quality Index (DLQI) and clinical information were evaluated in patients under active anticancer treatment using a questionnaire survey and their medical records review.ResultsOf 375 evaluated subjects with anticancer therapy, 136 (36.27%) and 114 (30.40%) were treated for breast cancer and colorectal cancer, respectively. We found that women, breast cancer, targeted agent use, and longer duration of anticancer therapy were associated with higher dermatology-specific quality of life distraction. In addition, itching, dry skin, easy bruising, pigmentation, papulopustules on face, periungual inflammation, nail changes, and palmoplantar lesions were associated with significantly higher DLQI scores. Periungual inflammation and palmoplantar lesions scored the highest DLQI.ConclusionWe believe our findings can be helpful to clinicians in counseling and managing the patients undergoing anticancer therapy.

show abstract

Daily skin care habits and the risk of skin eruptions and symptoms in cancer patients

Cited by 10 publications

References 15 publications

Correlates of oncologist-issued referrals for psycho-oncology services: what we learned from the electronic voluntary screening and referral system for depression (eVSRS-D)

Correlates of oncologist-issued referrals for psycho-oncology services: what we learned from the electronic voluntary screening and referral system for depression (eVSRS-D)

Pruritus in Patients Under Targeted Anticancer Therapy: A Multidimensional Analysis Using the 5-D Itch Scale

The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study

Contact Info

Product

Resources

About